<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00873236</url>
  </required_header>
  <id_info>
    <org_study_id>MTVERNHOSP-RD2007-114</org_study_id>
    <secondary_id>CDR0000637812</secondary_id>
    <secondary_id>ENH-RD2007-114</secondary_id>
    <secondary_id>EUDRACT-2008-006414-19</secondary_id>
    <secondary_id>EU-20917</secondary_id>
    <nct_id>NCT00873236</nct_id>
  </id_info>
  <brief_title>MRI Scans of Blood Vessel Changes Caused by Bevacizumab Alone or Given Together With Interferon Alpha-2a in Treating Patients With Stage III or Stage IV Kidney Cancer</brief_title>
  <official_title>Dynamic Contrast Enhanced MRI (DCE-MRI) Assessment of the Vascular Changes Induced With Bevacizumab Alone and in Combination With Interferon-α in Patients With Advanced Renal Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mount Vernon Cancer Centre at Mount Vernon Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Comparing results of MRI scans done after bevacizumab may help doctors predict a&#xD;
      patient's response to treatment and help plan the best treatment. It is not yet known whether&#xD;
      giving bevacizumab alone is more effective than giving bevacizumab together with interferon&#xD;
      alpha-2a in detecting kidney cancer.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is studying MRI scans of blood vessel changes caused&#xD;
      by bevacizumab to see how well it works compared with bevacizumab given together with&#xD;
      interferon alpha-2a in treating patients with stage III or stage IV kidney cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To establish whether bevacizumab-induced changes in dynamic contrast-enhanced (DCE)-MRI&#xD;
           vascular parameters are significantly enhanced by recombinant interferon alpha-2a.&#xD;
&#xD;
        -  To establish whether there is an interferon alpha-2a dose response in potentiating&#xD;
           bevacizumab-induced changes in DCE-MRI vascular parameters.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To correlate changes in DCE-MRI vascular parameters for each treatment group with&#xD;
           progression-free survival.&#xD;
&#xD;
        -  To correlate changes in DCE-MRI vascular parameters for each treatment group with tumor&#xD;
           response and changes in tumor size.&#xD;
&#xD;
        -  To correlate changes in DCE-MRI vascular parameters for each treatment group with other&#xD;
           surrogate biomarkers.&#xD;
&#xD;
        -  To assess the degree of change in baseline K^trans within each arm of treatment.&#xD;
&#xD;
        -  To investigate changes in diffusion and blood oxygen-level dependent MRI and their&#xD;
           correlation with other pharmacodynamic endpoints.&#xD;
&#xD;
        -  To assess the efficacy and safety profile of bevacizumab monotherapy or in combination&#xD;
           with low or standard doses of recombinant interferon alpha-2a.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are randomized to 1 of 3 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive bevacizumab IV over 30-90 minutes once every 2 weeks.&#xD;
&#xD;
        -  Arm II: Patients receive bevacizumab as in arm I and low-dose recombinant interferon&#xD;
           alpha-2a subcutaneously (SC) 3 times weekly beginning on day 0.&#xD;
&#xD;
        -  Arm III: Patients receive bevacizumab as in arm I and standard-dose recombinant&#xD;
           interferon alpha-2a SC 3 times weekly beginning on day 0.&#xD;
&#xD;
      After 8 weeks of treatment, recombinant interferon alpha-2a dosage may be modified or&#xD;
      discontinued at the discretion of the investigator. Treatment continues in the absence of&#xD;
      disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients undergo dynamic contrast-enhanced (gadopentetate dimeglumine) MRI scans at baseline&#xD;
      and weeks 2 and 6. Peripheral blood and serum samples are collected at baseline and weeks 2,&#xD;
      6, and 8 for analysis of surrogate biomarkers by flow cytometry and mRNA analysis by PCR.&#xD;
      Archival histopathological specimens are analyzed by IHC, fluorescence resonance-energy&#xD;
      transfer, and fluorescence lifetime-imaging. Urine samples are also collected at baseline for&#xD;
      proteomic profiling by MALDI-TOF.&#xD;
&#xD;
      After completion of study treatment, patients are followed at 30 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2008</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dynamic contrast-enhanced MRI defined changes in K-trans after 6 weeks of bevacizumab monotherapy or bevacizumab and low- or standard-dose recombinant interferon alpha-2a</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in vascular permeability (K-trans) and tumor hypoxia at 2 and 6 weeks post-commencement of treatment</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best overall response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment duration of bevacizumab and recombinant interferon alpha-2a</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment withdrawal</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose modification</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of circulating endothelial cells, circulating endothelial progenitors, and proangiogenic monocytic cells</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiogenic factors (e.g., VEGF) and hypoxia-regulated markers</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of DCE-MRI defined changes in K-trans with clinical response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of DCE-MRI defined changes in K-trans with surrogate biomarkers</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of diffusion MRI and blood oxygen-level dependent MRI changes and comparison with other pharmacodynamic markers</measure>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Kidney Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive bevacizumab IV over 30-90 minutes once every 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive bevacizumab as in arm I and low-dose recombinant interferon alpha-2a subcutaneously (SC) 3 times weekly beginning on day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm III</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive bevacizumab as in arm I and standard-dose recombinant interferon alpha-2a SC 3 times weekly beginning on day 0.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_label>Arm III</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant interferon alpha-2a</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_label>Arm III</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed advanced renal cell carcinoma&#xD;
&#xD;
               -  Metastatic (stage IV) disease&#xD;
&#xD;
               -  Locally advanced (unresectable stage III) disease&#xD;
&#xD;
          -  Previously untreated disease&#xD;
&#xD;
          -  Majority component of conventional clear-cell type is mandatory (tumors of mixed&#xD;
             histology should be categorized by the predominant cell type)&#xD;
&#xD;
          -  Good- or intermediate-prognosis disease as defined by Motzer score&#xD;
&#xD;
          -  Lesions measurable by RECIST criteria and amenable to dynamic contrast-enhanced MRI&#xD;
             scanning&#xD;
&#xD;
          -  No brain metastasis&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Life expectancy ≥ 12 weeks&#xD;
&#xD;
          -  ANC ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 8 g/dL (may be transfused to maintain or exceed this level)&#xD;
&#xD;
          -  Total bilirubin &lt; 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST and ALT &lt; 2.5 times ULN (&lt; 5 times ULN in patients with liver metastases)&#xD;
&#xD;
          -  Serum creatinine ≤ 1.5 times ULN&#xD;
&#xD;
          -  Urine dipstick for proteinuria &lt; 2+ OR &lt; 1 g of protein in 24-hour urine collection&#xD;
&#xD;
          -  INR ≤ 1.5&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile women must use effective contraception during and for 9 months after&#xD;
             completion of study treatment&#xD;
&#xD;
          -  No significant cardiovascular disease, defined as any of the following, within the&#xD;
             past 6 months:&#xD;
&#xD;
               -  NYHA class II-IV congestive heart failure&#xD;
&#xD;
               -  Unstable angina pectoris&#xD;
&#xD;
               -  Myocardial infarction&#xD;
&#xD;
          -  No significant vascular disease (e.g., aortic aneurysm, aortic dissection) or&#xD;
             symptomatic peripheral vacular disease&#xD;
&#xD;
          -  No evidence or history of recurrent thromboembolism (&gt; 1 episode of deep venous&#xD;
             thrombosis/pulmonary embolism) within the past 6 months, bleeding diathesis, or&#xD;
             coagulopathy&#xD;
&#xD;
          -  No inadequately controlled hypertension (defined as a BP of &gt; 150 mm Hg systolic&#xD;
             and/or &gt; 100 mm Hg diastolic on medication)&#xD;
&#xD;
          -  No history of hypertensive crisis or hypertensive encephalopathy&#xD;
&#xD;
          -  No stroke or transient ischemic attack within the past 6 months&#xD;
&#xD;
          -  No abdominal or tracheoesophageal fistula, gastrointestinal perforation, or&#xD;
             intra-abdominal abscess within the past 6 months&#xD;
&#xD;
          -  No HIV or hepatitis B or C infection&#xD;
&#xD;
          -  No active clinically serious bacterial or fungal infections (&gt; CTCAE grade 2)&#xD;
&#xD;
          -  No other infection &gt; CTCAE grade 2&#xD;
&#xD;
          -  No concurrent active second malignancy within the past 3 years other than nonmelanoma&#xD;
             skin cancers or post-treatment for localized prostate cancer&#xD;
&#xD;
          -  No gross ascites&#xD;
&#xD;
          -  No seizure disorder requiring medication&#xD;
&#xD;
          -  No serious non-healing wound, ulcer, or bone fracture&#xD;
&#xD;
          -  No contraindications to MRI scanning (e.g., history of claustrophobia or metal&#xD;
             fragment implantation)&#xD;
&#xD;
          -  No history of allergic reactions to contrast agents&#xD;
&#xD;
          -  No other significant medical illness or medically significant abnormal laboratory&#xD;
             finding that would, in the investigator's opinion, make the patient inappropriate for&#xD;
             this study, or would increase the risk associated with the patient's participation in&#xD;
             the study&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  More than 28 days since prior major surgery (including open biopsy) or radiotherapy&#xD;
             and recovered&#xD;
&#xD;
          -  More than 14 days since prior palliative radiotherapy to painful bone lesions and&#xD;
             recovered&#xD;
&#xD;
               -  Concurrent palliative radiotherapy for local pain control allowed&#xD;
&#xD;
          -  More than 7 days since prior core biopsy or other minor surgical procedure, excluding&#xD;
             placement of a vascular access device&#xD;
&#xD;
          -  More than 30 days since prior and no other concurrent investigational agents&#xD;
&#xD;
          -  No concurrent chronic daily intake of aspirin ≥ 325 mg/day or clopidogrel &gt; 75 mg/day,&#xD;
             or steroids (prednisone &gt; 12.5 mg/day or dexamethasone &gt; 2 mg/day), excluding inhaled&#xD;
             steroids&#xD;
&#xD;
          -  No concurrent bone marrow transplantation or stem cell rescue&#xD;
&#xD;
          -  Concurrent anticoagulation allowed provided INR &lt; 3 and INR is therapeutic on a stable&#xD;
             dose of coumarin-type anticoagulation or if patient is on a stable dose of low&#xD;
             molecular weight heparin for &gt; 2 weeks at the time of enrollment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Nathan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mount Vernon Cancer Centre at Mount Vernon Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <state>England</state>
        <zip>CB2 2QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-1223-245-151</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Marsden - London</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-20-7352-8171</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mount Vernon Cancer Centre at Mount Vernon Hospital</name>
      <address>
        <city>Northwood</city>
        <state>England</state>
        <zip>HA6 2RN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Nathan, MD</last_name>
      <phone>44-192-384-4966</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Churchill Hospital</name>
      <address>
        <city>Oxford</city>
        <state>England</state>
        <zip>OX3 7LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-186-574-1841</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Marsden - Surrey</name>
      <address>
        <city>Sutton</city>
        <state>England</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-20-8642-6011</phone>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2009</verification_date>
  <study_first_submitted>March 31, 2009</study_first_submitted>
  <study_first_submitted_qc>March 31, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2009</study_first_posted>
  <last_update_submitted>August 9, 2013</last_update_submitted>
  <last_update_submitted_qc>August 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 12, 2013</last_update_posted>
  <keyword>stage III renal cell cancer</keyword>
  <keyword>stage IV renal cell cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferon alpha-2</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

